Johnson & Johnson News

(Nasdaq: DNDN ) shares fell Thursday and Friday mostly because of data from potential competitor Johnson & Johnson (NYSE: JNJ ) . There was also a disclosure of an SEC investigation about its lowered guidance, but that seems to be a lesser concern than J&J's

and Johnson (JNJ) is at the lower end of a trading range which began late August 2011. As I have articulated in previous articles March 16, 2012 was a very important day with regard to the overall directional trend of the market. The Designated Market Maker

blood clots in patients with acute coronary artery disease. The Food and Drug Administration said a blood thinner from Johnson & Johnson appears to reduce life-threatening blood clots in high-risk patients, although it also increases the risk of internal bleeding.

Food and Drug Administration says a blood thinner from Johnson & Johnson appears to reduce life-threatening blood clots in high-risk patients, although it also increases the risk of internal bleeding.More >> The Food and Drug Administration said Monday that

Johnson & Johnson ($JNJ) builds the blockbuster pedigree of Xarelto, an FDA reviewer has given the thumbs-up to the new clot-busting drug as a treatment for the heart problem known as acute coronary syndrome. The staffers' recommendation of approval comes

7:11:05 AM Johnson & Johnson has won the first-ever monopolistic dispute between a producer and dealer on the Chinese mainland, with the court rejecting the dealer's compensation request of 14 million yuan ($2.21 million), said Shanghai No.1 Intermediate People's

Date | Search News Get Our Industry eNewsletter FREE email: 5/21/2012 8:16:00 AM U.S. drug reviewers said missing data for Johnson & Johnson's blood thinner Xarelto raised doubts about whether the drug actually reduced the risk of new heart attacks and strokes

of 3.29x. During FY11, the P/E ratio of the stock experienced a substantial increase and stood at 18.2x against 13x in FY10. Johnson & Johnson’s peer Novartis has a trailing PE ratio of 14.7 and yields 4.7%. The stock is expected to have a single digit PE

(AP) — The Food and Drug Administration says a blood thinner from Johnson & Johnson appears to reduce life-threatening blood clots in high-risk patients, although it also increases the risk of internal bleeding. The FDA posted its review of J&J's Xarelto for

— The Food and Drug Administration says a blood thinner from Johnson & Johnson appears to reduce life-threatening blood clots in high-risk patients, although it also increases the risk of internal bleeding. The FDA posted its review of J&J’s Xarelto for the